APG-2449 is under clinical development by Ascentage Pharma Group International and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APG-2449’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APG-2449 overview

APG-2449 is under development for the treatment of relapsed and refractory forms of non-small cell lung cancer, malignant pleural mesothelioma, esophageal cancer, ovarian cancer, fallopian tube cancer and primary peritoneal cancer. It is a third generation small molecule acts by targeting mutant ALK tyrosine kinase receptor (ALK), proto oncogene tyrosine protein kinase ROS (ROS1) and focal adhesion kinase (FAK). It is administered as capsule through oral route.

Ascentage Pharma Group International overview

Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It develops therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.

For a complete picture of APG-2449’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.